Meeting Banner
Abstract #2956

Investigation of lung cancer early detection with serum MRS biomarkers

Leo Ling Cheng1, Tjada A. Schult1,2, Mara J. Lauer1,3, Lindsey A. Vandergrift1, Mari A. Mino-Kenudson4, and David C. Christiani5,6
1Pathology, Massachusetts General Hospital, Charlestown, MA, United States, 2Charite Medical University, Berlin, Germany, 3Julius-Maximilians University, Wuerzburg, Germany, 4Pathology, Massachusetts General Hospital, Boston, MA, United States, 5Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, United States, 6Department of Medicine, Massachusetts General Hospital, Boston, MA, United States

To improve the survival rate of non-small cell lung cancer (LuCa) patients, an economically efficient screening method without radiation hazard is preferred. Based on our previously reported potential serum biomarkers for predicting survival and differentiating LuCa stages and types, we investigated the potential for these biomarkers to be used for early detection screening using LuCa serum samples from patients prior to their diagnoses and compared with those measured at the time of diagnosis. If developed, our findings could be used as a minimally-invasive early diagnosis scheme.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here